Asundexian for Stroke Prevention
(OCEANIC-STROKE Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing asundexian, a new medicine that prevents blood clots, in people who had a non-heart-related stroke or high-risk mini-stroke. The goal is to see if it works better at reducing future strokes without increasing bleeding risks. Asundexian is developed by Bayer AG and might prevent thrombosis without increasing bleeding.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop your current medications. However, it mentions that participants will receive asundexian or placebo in addition to standard antiplatelet therapy, suggesting you may continue your current antiplatelet medications.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications. However, it mentions that participants will receive the study treatment in addition to standard antiplatelet therapy, so you may continue taking antiplatelet medications.
What data supports the idea that the drug Asundexian for Stroke Prevention is an effective treatment?
The available research does not provide any data on Asundexian for Stroke Prevention. The studies listed focus on other treatments and conditions, such as bone formation in rabbits, shoulder pain, spinal stabilization, blood loss in surgery, and shoulder pain management. Therefore, there is no information here to support the effectiveness of Asundexian for Stroke Prevention.12345
What safety data exists for Asundexian for stroke prevention?
Is the drug Asundexian a promising treatment for stroke prevention?
The information provided does not directly address the effectiveness of Asundexian for stroke prevention. The articles focus on other treatments like aspirin and NXY-059, and discuss general challenges in developing effective stroke treatments. Therefore, we cannot conclude if Asundexian is promising based on this information.1112131415
How is the drug Asundexian unique for stroke prevention?
Asundexian is unique for stroke prevention because it is a novel anticoagulant that works differently from traditional antiplatelet drugs like aspirin, which have been used for many years. While aspirin prevents blood clots by stopping platelets from clumping together, Asundexian targets a different part of the clotting process, potentially offering an alternative for patients who may not respond well to existing treatments.1112131415
Eligibility Criteria
This trial is for adults who've recently had a non-cardioembolic ischemic stroke or high-risk TIA/mini-stroke and are receiving standard antiplatelet therapy. It's not for those with strokes from rare causes, atrial fibrillation/flutter, heart-related blood clots, or mechanical valves needing anticoagulation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either asundexian or placebo once a day in addition to standard antiplatelet therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Asundexian (BAY2433334)
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bayer
Lead Sponsor
Bill Anderson
Bayer
Chief Executive Officer since 2023
BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT
Michael Devoy
Bayer
Chief Medical Officer since 2014
MD, PhD